Signaling pathways in melanoma biology and new targeted therapeutic approaches

ABSTRACT
Despite the broad prevention programs and early detection and therapy progress, melanoma of skin is still responsible for 0.6% of deaths caused by tumour disease. Every year 300,000 patients are diagnosed and 60,000 die from the most malignant of skin cancer. Generally, melanoma is formed as a result of mutation of growth pathways responsible for proliferation and apoptosis. One of the most investigated pathway, mutated in 90% of melanomas, is RAS>RAF>MEK>ERK also known as mitogen-activated protein kinase (MAPK) pathway. The second one is phosphoinositide-3-OH kinase (PI3K) pathway. The better understanding of melanoma biology resulted in research of inhibitors, which can affect presented pathways and prevent uncontrolled proliferation of melanoma. The BRAF inhibitors vemurafenib and dabrafenib and MEK inhibitor trametinib seem to be the most successful ones. Recent advances in biology of melanoma provided new interesting therapeutic targets. One of the most inquiring is microphthalmia associated transcription factor (MITF), the principal regulator of melanocyte lineage. MITF perform the role of so-called ‘survival’ or ‘addiction’ oncogene. Moreover, the interleukin-1 receptor-associated kinases (IRAKs) might clarify the connection between the inflammatory environment and melanoma carcinogenesis. IRAKs play a key role as mediators of toll-like receptor (TLR) and interleukin-1 receptor (IL1R) in inflammation signalling processes. Moreover, it was observed that metformin cause cell cycle arrest in melanoma cells, secondly leading to activation of autophagy and apoptosis. Although due to targeted and immunotherapy the prognosis of patients with metastatic melanoma is incomparably better, melanoma in its advanced stadium is still predominantly lethal. Therefore, the most present research concentrates on acquired resistance against targeted therapy.

Key words: melanoma, targeted therapy, dermatology, oncology

Introduction
Melanocytes are melanin producing cells that anatomically exist mainly in the epidermal cell population, but have origins in neural crest cells. As a pigment producer they are responsible for skin and hair colour. They also play a key role in prevention of skin damage caused by UV radiation. In unaffected skin they are situated in basal layer of epidermis where their metabolism is regulated by keratinocytes [1]. Mutations in oncogenes enable melanocytes to avoid this regulation, then unrestricted spread and consequently develop the skin cancer, melanoma. Undergoing radial and vertical growth phase melanoma can form malignant tumour and then infiltrate the vascular or lymphatic system [2]. Considering different clinical pathology diagnosis, etiology, biologic properties, and prognosis among cutaneous melanoma most authors distinguish nodular melanoma (NM), superficial spreading melanoma (SSM), lentigo maligna melanoma (LMM), and acral-lentiginous melanoma (ALM) [3]. Studies on cell-signaling mechanisms enabled to determine the pathways controlling growth and division of cells. Some of them become often hyperactivated leading to uncontrolled proliferation of cancer cells.

Epidemiology
As the epidemiological research shows that melanoma of skin is responsible for 0.6% of deaths caused by tumour disease. Every year 300,000 patients are diag-
nosed and 60,000 die from the most malignant of skin cancer [4]. Normally, once the skin cancers are early diagnosed and receive appropriate management, they reach 95% of 5-year survival rate. However, cutaneous malignant melanoma shows relevant higher morbidity and mortality and is responsible for 65% of all skin cancer deaths [5]. There are several factors, which contribute to the increasing incidence of skin cancers. Among them, the exposure to sunlight and other sources of UV irradiation is often associated with development of melanoma. Moreover, rising exploitation of sunlamps, UV irradiation is often associated with development of them, the exposure to sunlight and other sources of ute to the increasing incidence of skin cancers. Among cer deaths [5]. There are several factors, which contrib-

Melanoma biology

Melanoma occurs as a result of multiple mutations that cause deregulation of several principal cell signalling pathways, which leads to uncontrolled proliferation and formation of melanoma. Understanding these processes helps to undertake specific and personal-

The role of MAPK, PI3K and PTEN pathways

One of the most investigated pathway, mutated in 90% of melanomas, is RAS>RAF>MEK>ERK (also known as mitogen-activated protein kinase (MAPK) pathway). Its activation triggers the mitosis of cells resulting in uncontrolled proliferation of cells [7]. In 50–70% of cases, the pathway is upregulated by BRAF mutation (the most common is V600E BRAF) and in 15–30% by N-ras mutation [8, 9].

It was proven that the single mutation might have an effect on several aspects of tumour genesis. In melanoma case the BRAF mutation, besides increased proliferation of melanoma cells results in upregulation of VEGF, the angiogenic factor [10].

The second major melanoma growth pathway is phosphoinositide-3-OH kinase (PI3K) pathway. PI3Ks are a family of lipid kinases acting as lipid second messengers that affect downstream regulators, among others protein kinase B (PKB). PI3K signalling regulates cell survival, proliferation and growth. The supervisory function in this pathway is performed by PTEN, the factor responsible for signal termination. PTEN loss of function, resulting in uncontrolled cancer proliferation, is present in 5–20% of melanoma [11].

Significant is that NRAS mutation does not generally occur simultaneously neither with BRAF nor with PTEN mutation, whereas the changes in both BRAF and PTEN are present in 20% of cases. This observation supports the conclusion that BRAF and PI3K are activated downstream of RAS. BRAF and PTEN operate on distinct genetic pathways and could cooperate to promote melanoma proliferation [12, 13]. Moreover, some of the N-ras mutations seems to be typical for congenital melanocytic neavi, but are not characteristic to dysplastic melanocytic neavi [14].

The role of MITF and p16 regulators

An interesting regulator of melanocyte lineage is microphthalmia associated transcription factor (MITF). MITF perform the role of so-called ‘survival’ or ‘addi-

The role of IRAK in deregulation of inflammation

There seems to be relevant correlation between inflammation and genesis of tumours. Some of the pathways partly clarify this reciprocal connection. The interleukin-1 receptor-associated kinases (IRAKs) play a key role as mediators of toll-like receptor (TLR) and interleukin-1 receptor (IL1R) signalling processes. It was revealed that TLR/IL1R-mediated signalling con-
controls diverse cellular processes including inflammation, apoptosis, and cellular differentiation [21, 22]. Importance of IRAK receptors in deregulation of inflammation, increasing NF-κB activity and formation of cancer is currently investigated.

IRAK1 and IRAK4 are overexpressed in melanoma cell lines and their role is currently investigated. Overexpression of IRAK family members and its role in inflammation process [21, 23]. The interleukin-1 receptor-associated kinases (IRAKs) play a key role as mediators of toll-like receptor (TLR) and interleukin-1 receptor (IL1R) presented on the cell membrane. The intracellular signalling processes result in increasing NF-κB activity and deregulation of inflammation. Two kinases IRAK1 and IRAK4 are overexpressed in melanoma cell lines and their role is currently investigated.

IRAK1 and IRAK4 are overexpressed and activated in melanoma cell lines. The attenuating IRAK-1,-4 signalling with pharmacological inhibitors in vitro increased vinblastine impact on melanoma cell death [23]. Further, in a xenograft mouse, combined therapy with IRAK inhibitors had significant impact on prolonged survival [23]. IRAKs seem to be promising targets to enhance the therapeutic response, but until now there are no studies proving the effectiveness of IRAK inhibitors on melanoma patients in vivo.

**Targeted treatment possibilities**

The better understanding of melanoma biology resulted in the research of inhibitors, which can affect presented pathways preventing uncontrolled proliferation of melanoma. The most successful seem to be BRAF inhibitors vemurafenib [24] and dabrafenib [25] and MEK inhibitor trametinib [26]. The trials on vemurafenib showed the response rates of more than 50% in patients with metastatic melanoma with the V600E BRAF mutation. Moreover it significantly reduced the risk of death and disease progression, as compared with chemotherapy with dacarbazine [27]. Letter on, the studies on dabrafenib showed similar results on patient with advanced-stage metastatic melanoma [25]. As the responses seem to be short-lived next trials were focused on MEK inhibition with trametinib [28].

Long-term investigation showed that patients undergoing targeted therapy developed resistance to BRAF inhibitors. MAPK reactivation mechanisms were acquired by N-ras mutations. Mutant BRAF amplification and alternative splicing were detected in 70% of patients. PI3K-PTEN-AKT upregulation was observed in 22% of progressive melanoma disease [29]. Moreover, the most severe side effect of BRAF inhibition was the development of secondary skin tumours, originating from a paradoxical activation of the MAPK pathway in cells without BRAF mutation [27]. The potential solution to this problem may be provided by combined therapy. The results of trial with dabrafenib plus trametinib vs vemurafenib monotherapy showed encouraging results enhancing overall survival in previously untreated patients with metastatic melanoma [30–32]. Targeted medicaments currently approved by FDA for metastatic melanoma targeted treatment were presented in Table 1.

Although presented results seem to be promising there is still the vast part of responses that are not typically complete or durable. Therefore, the major focus is required to identify and target the mechanisms of resistance. Not only combined approaches among targeted but also immune therapy might provide the extended overall survival and enhance the quality of life of the patients with metastatic melanoma.

### Table 1. Targeted medicaments currently approved by FDA for metastatic melanoma targeted treatment

<table>
<thead>
<tr>
<th>Name of medicaments</th>
<th>Pathway</th>
<th>Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Encorafenib and binimetinib combination</td>
<td>BRAF MEK kinases inhibitor</td>
<td>[39]</td>
</tr>
<tr>
<td>Cobimetinib and vemurafenib combination</td>
<td>BRAF and MEK kinases inhibitor</td>
<td>[40]</td>
</tr>
<tr>
<td>Trametinib</td>
<td>MEK inhibitor</td>
<td>[28]</td>
</tr>
<tr>
<td>Trametinib and dabrafenib combination</td>
<td>BRAF and MEK kinases inhibitor</td>
<td>[30–32]</td>
</tr>
<tr>
<td>Dabrafenib</td>
<td>BRAF kinase inhibitor</td>
<td>[25]</td>
</tr>
<tr>
<td>Vemurafenib</td>
<td>BRAF kinase inhibitor</td>
<td>[41]</td>
</tr>
</tbody>
</table>
Metformin induces AMPK-dependent and independent melanoma cell death

Metformin is generally used for Diabetes treatment but it might find its application in oncology. The mechanism of action of metformin has not been fully elucidated. So far, the activation of AMP-activated protein kinase (AMPK) in mitochondria seems to provide a rational explanation [33].

Metformin uses AMPK-dependent and independent pathway to induce melanoma cell death [34]. It was also observed that metformin cause cell cycle arrest in melanoma cells, secondly leading to activation of autophagy and apoptosis [35]. Moreover, Hirsch et al. have proven that Metformin inhibits the inflammatory response preventing cellular transformation and inhibiting cancer growth [36].

Metformin is known to alter the mitochondrial metabolism, what secondly influence the tumour microenvironment [37]. Its role as an adjuvant medicament against melanoma is currently undergoing trials among others with targeted therapy agents [34, 38].

Conclusion

Years of research on melanoma cell biology finally gave rise to relatively safe and efficient therapies. The knowledge of specific proliferation pathways together with progress in oncoimmunology resulted in the development of targeted drugs. Those can be applied, when other therapeutic options, such as surgery are exploited. Although the prognosis of patients with metastatic melanoma is incomparably better, melanoma in its advanced stadium is still predominantly lethal. Therefore, the present research concentrates on acquired resistance against targeted therapy.

Acknowledgements

The work was created as part of the activity of the Student Research Group of Biology of Cancer Cell at the Wrocław Medical University (SKN No. 148) and partially by Statutory Funds of Wrocław Medical University (Department of Molecular and Cellular Biology).

References


www.journals.viamedica.pl/medical_research_journal


